Literature DB >> 17110287

Antiepileptic drugs in development.

John R Pollard1, Jacqueline French.   

Abstract

BACKGROUND: Despite the success of several new antiepileptic drugs, about one third of patients with epilepsy are not seizure free on medication. Improvement in this situation might lie in drugs that are currently in development. RECENT DEVELOPMENTS: Some new antiepileptic drugs are modifications of those already available, referred to in this Rapid Review as evolutionary drugs. These modifications of existing drugs are developed to improve effectiveness, often by increasing tolerability. Other drugs work by new mechanisms and are usually discovered through screening of animal models. WHERE NEXT? The large number of drugs currently in clinical trials provides a measure of hope for patients whose epilepsy is not controlled with currently available medication. In the future, this range of antiepileptic drugs will probably increase because of the use of new animal models, discovery of new basic mechanisms of epileptogenesis, acceleration of proof of principle studies in people, and development of new methods of drug delivery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110287     DOI: 10.1016/S1474-4422(06)70627-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  3 in total

Review 1.  Antiepileptic drugs in development pipeline: A recent update.

Authors:  Harjeet Kaur; Baldeep Kumar; Bikash Medhi
Journal:  eNeurologicalSci       Date:  2016-06-17

2.  Evaluation of anticonvulsant actions of dibromophenyl enaminones using in vitro and in vivo seizure models.

Authors:  Mohamed G Qaddoumi; Kethireddy V V Ananthalakshmi; Oludotun A Phillips; Ivan O Edafiogho; Samuel B Kombian
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

3.  Novel actions of oxazolidinones: in vitro screening of a triazolyloxazolidinone for anticonvulsant activity.

Authors:  Samuel B Kombian; Oludotun A Phillips
Journal:  Med Princ Pract       Date:  2012-12-21       Impact factor: 1.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.